Speaker illustration

Professor Alessandro Cataliotti

Oslo University Hospital Rikshospitalet, Oslo (Norway)

ProANP31-67 ameliorates adverse cardiac remodeling and improves systolic and diastolic functions in a preclinical model of cardiorenal syndrome

Event: Frontiers in CardioVascular Biomedicine 2022

Topic: Drugs, Drug Targets

Session: Moderated poster 9 - Drugs


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb